Andrew Reardon - Nov 1, 2022 Form 3 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role: Chief Legal Officer and Secretary Exhibit 24 - Power of Attorney.
Signature: /s/ Andrew Reardon
Stock symbol: LGND
Transactions as of: Nov 1, 2022
Transactions value $: $0
Form type: 3
Date filed: 11/7/2022, 07:23 PM
Next filing: Dec 1, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	LGND	Common Stock						12K	Nov 1, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	LGND	Employee Stock Option (right to buy)							Nov 1, 2022	Common Stock	72.9K	$52.27	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 8,581 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire.
F2	The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter.

Remarks:

Chief Legal Officer and Secretary Exhibit 24 - Power of Attorney.